Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome

Journal of Endocrinological Investigation

Volumn 31, Issue 5, 2008, Pages 400-405

  Kristo, Cybele ^a,b   Ueland, T ^a,b   Godang, K ^a   Aukrust, P ^a,b   Bollerslev, J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiovascular risk; Cushing's syndrome; Glucocorticoid; IL 8; Inflammation; Osteoprotegerin; sCD40L; slCAM 1

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CORTISONE ACETATE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; OSTEOPROTEGERIN; VON WILLEBRAND FACTOR;

ADRENAL CORTEX ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS ADENOMA; INFLAMMATION; LOW DRUG DOSE; MALE; PHENOTYPE; TRANSSPHENOIDAL SURGERY;

EID: 48949116994     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346383     Document Type: Article

References (32)

1. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Enclocrinol (Oxf) 1994, 40: 479-84.
2. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Enclocrinol Metab 2001, 86: 117-23.
3. Amaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004, 7: 253-6.
4. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Enclocrinol Metab 2003, 88: 2527-33.
5. Colao A, Pivonello R, Auriemma IRS, et al. New perspectives in the medical treatment of acromegaly. J Enclocrinol Invest 2005, 28 (11 Suppl): 58-66.
6. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111: 3481-8.
7. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91: 281-91.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352: 1685-95.
9. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of clexamethasone for prevention of neointimal proliferation in a rat model of balloon angio-plasty. J Clin Invest 1994, 93: 1243-9.
10. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest 1973, 52: 599-607,
11. Kristo C, Godang K, Ueland T, et al. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in enclogenous Cushing's syndrome. Eur J Enclocrinol 2002, 146: 389-95.
12. Kristo C, Jemtland R, Ueland T, Godang K, Bollerslev J. Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. Eur J Enclocrinol 2006, 154:109-18.
13. Arnaldi G, Angeh A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Enclocrinol Metab 2003, 88: 5593-602.
14. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-on-set GH deficiency. Eur J Enclocrinol 2006, 154: 537-43.
15. Ueland T, Bollerslev J, Godang K, Willer F, Frøland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Enclocrinol 2001, 145: 685-90.
16. Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT. Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta 2002, 322: 163-8.
17. Aukrust P, Damas JK, Solurn NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol 2004, 43: 2326-8.
18. Fukakusa M, Bergeron C, Tulic MK, et al. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inclucible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005, 115: 280-6.
19. Homma T, Kato A, Hashimoto N, et al. Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004, 31: 463-9.
20. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med 2004, 36: 98-118.
21. BoisverL WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000, 21: 129-37.
22. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106: 1192-4.
23. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004, 35: 1636-41.
24. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-6.
25. Sandberg WJ, Yndestad A, Øie E, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26: 857-63.
26. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular, disease. Clin Chim Acta 2006, 368: 33-47.
27. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentalorna. Exp Clin Enclocrinol Diabetes 2000, 108: 294-8.
28. Voisin C, Christofilos D, Del Fatti N, et al. Size-dependent electron-electron interactions in metal nanoparticles. Phys Rev Lett 2000, 85: 2200-3.
29. Casonato A, Pontara E, Boscarc, M, et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis 1999, 10: 145-51.
30. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Enclocrinol Metab 2002, 87: 3662-6.
31. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004, 116 (Suppl 6A): 9S-16S.
32. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109: 2175-80.